Related Experiment Video
Updated: Jul 13, 2026
09:46
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Drug-induced thrombocytopenia.
Gian Paolo Visentin1, Chao Yan Liu
1Department of Pediatrics, University at Buffalo, The State University of New York, 3435 Main Street BRB, Room 422, Buffalo, NY 14214, USA. visentin@buffalo.edu
Hematology/Oncology Clinics of North America
|August 2, 2007
Summary
Drug-induced thrombocytopenia (DIT) requires prompt identification and withdrawal of the causative agent to prevent serious bleeding or thrombosis. DIT differs from idiopathic thrombocytopenic purpura based on drug history and lab results.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Drug-induced thrombocytopenia (DIT) is a frequent clinical issue.
- Prompt intervention is crucial to avoid severe bleeding or thrombosis, particularly with heparin.
- DIT diagnosis relies on drug history and laboratory findings, differentiating it from other thrombocytopenic disorders.
Purpose of the Study:
- To summarize the key aspects of drug-induced thrombocytopenia.
- To highlight the importance of rapid diagnosis and management.
- To differentiate DIT from idiopathic thrombocytopenic purpura.
Main Methods:
- Review of clinical and laboratory findings associated with DIT.
- Analysis of mechanisms leading to thrombocytopenia in DIT.
- Comparison of DIT with idiopathic thrombocytopenic purpura.
Main Results:
- DIT is characterized by decreased platelet production or accelerated platelet destruction.
- Immune-mediated destruction is a common mechanism in DIT.
- Distinguishing DIT from other causes of low platelets is essential for effective treatment.
Conclusions:
- Early recognition and removal of the offending drug are paramount in managing DIT.
- Understanding the underlying mechanisms aids in clinical decision-making.
- DIT is a distinct entity requiring specific diagnostic and therapeutic approaches.
Related Concept Videos
01:01Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...